- Home
- GNW vs BEAM Comparison
GNW vs BEAM Comparison
Compare GNW & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNW | BEAM |
|---|---|---|
| Founded | 1871 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.0B |
| IPO Year | 2004 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GNW | BEAM |
|---|---|---|
| Price | $8.95 | $33.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $10.50 | ★ $50.75 |
| AVG Volume (30 Days) | ★ 2.4M | 1.8M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $7,301,000,000.00 | $24,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $33.77 |
| P/E Ratio | $74.50 | ★ N/A |
| Revenue Growth | 0.08 | ★ 33.33 |
| 52 Week Low | $7.13 | $15.60 |
| 52 Week High | $9.45 | $36.44 |
Technical Indicators
Market Signals| Indicator | GNW | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 54.71 | 61.67 |
| Support Level | $8.23 | $26.96 |
| Resistance Level | $9.21 | $36.44 |
| Average True Range (ATR) | 0.16 | 2.15 |
| MACD | 0.03 | 0.30 |
| Stochastic Oscillator | 88.39 | 96.53 |
Price Performance
Historical ComparisonAbout GNW Genworth Financial Inc
Genworth Financial Inc is a diversified insurance holding company that provides various mortgage and life insurance products. The company has four main operating business segments: Enact, Closed Block segment, and Corporate and Other. The company's product portfolio includes various financial products such as traditional life insurance, mortgage insurance, fixed annuities, and variable annuities. The majority of the revenue is generated by the Enact segment. The company earns the maximum of its revenue in the United States.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.